OKYO Pharma (NASDAQ:OKYO) Research Coverage Started at Piper Sandler

Piper Sandler began coverage on shares of OKYO Pharma (NASDAQ:OKYO) in a report released on Friday, Marketbeat reports. The brokerage issued an overweight rating and a $7.00 price target on the stock.

A number of other equities analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of OKYO Pharma in a research note on Thursday, January 29th. Finally, B. Riley Financial initiated coverage on OKYO Pharma in a research report on Monday, December 8th. They set a “buy” rating and a $5.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, OKYO Pharma has an average rating of “Hold” and a consensus target price of $6.33.

OKYO Pharma Price Performance

NASDAQ OKYO opened at $1.70 on Friday. The business’s 50 day moving average price is $2.11 and its 200-day moving average price is $2.21. OKYO Pharma has a fifty-two week low of $1.03 and a fifty-two week high of $3.35.

OKYO Pharma (NASDAQ:OKYO) last posted its quarterly earnings data on Friday, January 30th. The company reported ($2.28) EPS for the quarter, missing the consensus estimate of ($0.07) by ($2.21). On average, equities research analysts expect that OKYO Pharma will post -0.17 earnings per share for the current year.

Institutional Investors Weigh In On OKYO Pharma

A number of large investors have recently modified their holdings of OKYO. Citadel Advisors LLC purchased a new stake in shares of OKYO Pharma during the 3rd quarter worth $31,000. Renaissance Technologies LLC increased its holdings in shares of OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after acquiring an additional 96,800 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in OKYO Pharma during the fourth quarter worth approximately $36,000. 2.97% of the stock is owned by hedge funds and other institutional investors.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.